netFormulary
 Report : A-Z of formulary items 06/07/2020 00:28:36
[Back]
 
Section Name Details
07.04.03  Pentosan polysulfate sodium

Approved for use in line with NICE TA610  

13.02.01 50:50 white soft paraffin and liquid paraffin ointment  
05.03.01 Abacavir Ziagen®

Tablet, Oral Solution

05.03.01 Abacavir and Lamivudine Kivexa®

Tablet

05.03.01 Abacavir and Lamivudine and Zidovudine Trizivir®

Tablet

10.01.03 Abatacept Orencia®

injection

02.09 Abciximab 

Injection

08.03.04.02 Abiraterone Zytiga®

tablet

04.10.01 Acamprosate Campral EC®

to be initiated  and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service

06.01.02.03 Acarbose Glucobay®

Tablet

02.08.02 Acenocoumarol Sinthrome®
11.06 Acetazolamide Diamox®

250mg Tablets

250mg MR Capsules

Red Traffic Light 500mg Injection (Hospital Initiated)

11.08.02 Acetycholine 1%, Mannitol 3% Solution  

Acetycholine 1%, Mannitol 3% Solution

11.08.02 Acetylcholine Chloride Miochol-E®

In 2ml Intraocular

03.07 Acetylcysteine 
11.08.01 Acetylcysteine 5% with Hypromellose 0.35% 

Acetylcysteine 5% with Hypromellose 0.35% Eye Drops

05.03.02.01 Aciclovir 

Green   Tablet, Suspension

 

Red   Injection & Infusion

11.03.03 Aciclovir eye ointment 3% Zovirax®
13.05.02 Acitretin Capsules  
03.01.02 Aclidinium Eklira Genuair®

DPI

03.01.04 Aclidinium and formoterol inhaler Duaklir Genuair ®
01.05.03 Adalimumab 

To be in accordance with the associated NICE Technical Appraisals  

10.01.03 Adalimumab Humira®
13.05.03 Adalimumab 
13.06.01 Adapalene  Differin®

Gel and cream

13.06.01 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel Epiduo ®
05.03.03.01 Adefovir Dipivoxil Hepsera®

Tablet

02.03.02 Adenosine Adenocor®

injection

08.02.02 AdoPORT ® Tacrolimus

Red NHSE funded indication are usually Hospital Only

03.04.03 Adrenaline / epinephrine EpiPen® & Jext®
02.07.03 Adrenaline / Epinephrine 1 in 10,000 (dilute) 
08.02.02 Advagraf ® 

Red NHSE funded indication are usually Hospital Only

08.01.05 Afatinib Giotrif®
11.08.02 Aflibercept 

Injection

20 Ajmaline 

50mg/10ml Injection

Consultant Cardiologist only for diagnosis of Brugada syndrome

05.05.01 Albendazole  

unlicensed unlicensed

Tablet 400mg (unlicensed import, some products are chewable)

Specialist recommendation (discuss specific therapies and investigations with a Microbiologist or an Infectious Disease specialist)

08.01.05 Alectinib Alecensa®

CAPSULE

08.02.03 Alemtuzumab Lemtrada®

infusion

06.06.02 Alendronic Acid 

Tablets 10mg, 70mg

(including 70 mg effervescent Tablets for PEG/NG tube patient administration)

04.07.02 Alfentanyl  

Injection

07.04.01 Alfuzosin 

Tablet, Tablet m/r

03.04.01 Alimemazine Vallergan®
02.14 Alirocumab Praluent®

Subcutaneous Injection

13.05.01 Alitretinoin Toctino®

NICE TA177:Alitretinoin for the treatment of severe chronic hand eczema

10.01.04 Allopurinol 

tablets

06.01.02.03 Alogliptin Vipidia▼®

Tablet

07.04.05 Alprostadil Caverject®

Injection, Dual chamber

Intracavernosal injection 10 micrograms, 20 micrograms


- specialist initiation.

07.04.05 Alprostadil Viridal® Duo

Intracavernosal injection 10 micrograms, 20 micrograms, 40 micrograms

07.04.05 Alprostadil MUSE®

Urethral application 125 micrograms, 250 micrograms, 500 micrograms, 1mg

02.10.02 Alteplase Actilyse®

injection

01.01.01 Aluminimum Hydroxide 
04.09.01 Amantadine 
05.01.04 Amikacin 

Injection

02.02.03 Amiloride Hydrochloride 
03.01.03 Aminophylline 

Tablet MR - Restricted for existing patients only, new patients to start on theophylline.

Redinjection

02.03.02 Amiodarone 

Tablets

Red Traffic Light Injection is hospital only

04.02.01 Amisulpride 

Tablet

Oral Solution

04.03.01 Amitriptyline 

Tablets

Syrup

02.06.02 Amlodipine 

Tablets

05.01.01.03 Amoxicillin 

Capsules

Syrup

Sachets

 

05.01.01.03 Amoxicillin 

injection

05.02 Amphotericin Abelcet ® AmBisome ® Fungizone ®

Infusion

08.03.04.01 Anastrozole 

1mg Tablet

05.02.04 Anidulafungin Ecalta®

infusion

11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®

Eye Drops

01.07.01 Anusol ® 

ointment
cream
suppositories

01.07.02 Anusol-HC 
02.08.02 Apixaban Eliquis®

Tablets

04.09.01 Apomorphine 
11.08.02 Apraclonidine 

Eye Drop 0.5%

Eye Drops 1% Single Dose Units

10.01.03 Apremilast  (Ortezla® )

Tablet
- approved in line with NICE TA419 and NICE TA433

13.05.03 Apremilast Otezla®
04.06 Aprepitant Emend®

Use as per HYCCN Network

 

13.02.01 AproDerm ® Colloidal Oat Cream  

For use when a paraffin-free emollient is required 

01.06.03 Arachis Oil 

enema

04.02.01 Aripiprazole 

Tablets, Orodispersible tablets,Oral solution
Injection 7.5mg/ml(secondary care only)

08.01.05 Arsenic Trioxide Trisenox®

Infusion

05.04.01 Artemether with lumefantrine Riamet®

tablets (treatment of uncomplicated Falciparum)

01.01.01 Asilone 

Restricted use for palliative care only

02.09 Aspirin  

Soluble Tablets

05.03.01 Atazanavir Reyataz®

Capsule

02.04 Atenolol 

Tablets, Syrup

Red Traffic Light Injection

08.02.04 Atezolizumab  (Tecentriq®)

Concentrate for solution for infusion 

04.04 Atomoxetine Strattera®

Atomoxetine Capsules

02.12 Atorvastatin 
07.01.03 Atosiban Tractocile ®

Injection

Atosiban Injection 7.5mg/ml, 0.9ml vial.

Atosiban Concentrate for Intravenous Infusion 7.5mg/ml, 5ml vial.

11.05 Atropine 

Eye Drops 0.5%

Eye Drops 1%

Eye Ointment 1%

Minims 1%

08.02.04 Avelumab  (Bavencio®)

Concentrate for solution for infusion

08.02.04 Axicabtagene ciloleuce (Yescarta®)
08.01.05 Axitinib Inlyta®

Tablet

08.01.03 Azacitidine Vidaza®

Injection

01.05.03 Azathioprine 

Tablets

08.02.01 Azathioprine 

Tablets 25mg, 50mg

10.01.03 Azathioprine 

tablet

05.01.05 Azithromycin 

Capsules, Suspension

05.01.02.03 Aztreonam 

Injection

Group three restricted

Microbiologist authorisation only

10.02.02 Baclofen 

syrup

tablets

11.06 Balanced Salt Solution 

Preservative Free 15ml

Preservative Free 500ml

01.05.01 Balsalazide colazide

capsules

10.01.03 Baricitinib  (Olumiant®)

tablet

08.02.02 Basiliximab Simulect®

Injection 

03.02 Beclometasone Qvar®kelhale®
03.02 Beclometasone Clenil Modulite®
03.02 Beclometasone and formoterol Fostair NEXThaler®
03.02 Beclometasone and formoterol Fostair®
03.02 Beclometasone, Formeterol and Glycopyrronium Trimbow®

Triple dose inhaler available as a pressurised metered dose inhaler delivering a solution with a nominal dose per actuation of 87 micrograms beclometasone dipropionate, 5 micrograms formoterol fumarate dihydrate and 9 micrograms glycopyrronium 

03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®
10.01 Belimumab Benlysta®
08.01.01 Bendamustine 

infusion

02.02.01 Bendroflumethiazide 
05.01.01.01 Benzathine Penicillin 
13.06.01 Benzoyl Peroxide  
13.06.01 Benzoyl Peroxide and Clindamycin Gel  Duac Once Daily
05.01.01.01 Benzylpenicillin 

Injection

03.05.02 Beractant Survanta®

peadiatrics

13.09 Betadine® 
04.06 Betahistine Dihydrochloride 

Tablets

06.03.02 Betamethasone 

soluble tablets, Injection

betnesol <sup>®</sup>

10.01.02.02 Betamethasone 
11.04.01 Betamethasone  

Eye Drops 0.1%

Eye Ointment 0.1%

13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®
13.04 Betamethasone (as Valerate) 0.025% 
13.04 Betamethasone (as Valerate) 0.1% Betnovate®
13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet®
13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm®
11.04.01 Bethamethasone with Neomycin 

Eye Drops

Eye Ointment

08.01.05 Bevacizumab Avastin®

Infusion

11.08.02 Bevacizumab Intravitreal Syringe Avastin®

unlicensedunlicensed

5mg/0.2ml Intravitreal Syringe

08.01.05 Bexarotene Targretin®
02.12 Bezafibrate 

Tablets and Modified Release Tablets

08.03.04.02 Bicalutamide 

50mg and 150mg tablets

11.06 Bimatoprost 

Eye Drops 100mcg/ml

Eye Drops 300mcg/ml UDVs for Preservative Sensitivity

11.06 Bimatoprost with Timolol 

Bimatoprost 300mcg/ml, Timolol 5mg/ml Eyr drops (UDVs for Preservative Sensitivity)

06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Vial, Cartridge, Prefilled pen 

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix 25

lispro 25% / Lispro Protamine 75%

KwikPen, 3mL

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix 50

Lispro 50%, Protamine 75%

KwikPen,  3mL cartridge

06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Vial Cartridge, Kwikpen

01.06.02 Bisacodyl 

Tablets, suppositories

02.04 Bisoprolol 

Tablets

First line use for all patients with systolic LV dysfunction

 

02.08.01 Bivalirudin Angiox®
08.01.02 Bleomycin 

injection

08.02 Blinatumomab Blincyto®

Infusion

05.03.03.02 Boceprevir Victrelis®

capsule

08.01.05 Bortezomib Velcade®
08.01.05 Bosutinib Bosulif®

Tablet

04.07.04.02 Botulinum Toxin Type A botox®

Injection Vials

04.09.03 Botulinum Toxin Type A Botox®

injection

08.01.05 Brentuximab vedotin Adcetris®

infusion

11.06 Brimonidine  

Eye Drops 0.2%

11.06 Brimonidine 0.2% with Timolol 0.5% 

Eye Drops Brimonidine 0.2% with Timolol 0.5%

11.06 Brinzolamide 

Eye Drops 1%

11.06 Brinzolamide 1% with Timolol 0.5%  

Eye Drops Brinzolamide 1%, Timolol 5mg/ml

11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza®

Brinzolamide 10mg/ml & brimonidine 2mg/ml Eye Drops

04.08.01 Brivaracetam Briviact®

Tablets

Liquid

11.04.02 Bromfenac  

Eye Drops 0.09%

06.07.01 Bromocriptine Parlodel®

Tablets

01.05.02 Budesonide Entocort®

Modified Release Capsules

03.02 Budesonide 

Easyhaler, dry powder inhalation

Amber Nebules -acute treatment of croup

03.02 Budesonide and formoterol Fobumix Easyhaler®

easyhaler

03.02 Budesonide and formoterol DuoResp Spiromax®
03.02 Budesonide and formoterol Symbicort®
02.02.02 Bumetanide 

Tablet, Liquid

Red Traffic Light Injection

04.10.03 Buprenorphine Subutex®

Sublingual Tablets

 

To be commenced by specialist service only and prescribing must be in collaboration with the advice from substance misuse services.  

04.10.03 Buprenorphine and Naloxone Suboxone®

Tablets

 

To be commenced by specialist service only and prescribing must be in collaboration with the advice from the substance misuse services

06.07.02 Buserelin 

Nasal Spray

08.03.04.02 Buserelin 
04.01.02 Buspirone Hydrochloride 

tablets

08.01.01 Busulfan 

tablet, infusion

03.04.03 C1 Esterase Inhibitor Berinert®
08.01.05 Cabazitaxel Jevtana®

infusion

06.07.01 Cabergoline 

500 microgram tablets

08.01.05 Cabozantinib Cabometyx®

Tablet

13.05.02 Calcipotriol Ointment  
13.05.02 Calcipotriol Scalp Application  
13.05.02 Calcipotriol with Betamethasone  Dovobet ® Enstillar®
06.06.01 Calcitonin (salmon) / Salcatonin 

Injection 400u in 2ml, 100 units/ml, 1ml amp

08.01 Calcium Folinate 

Tablet, injection

06.01.02.03 Canagliflozin Invokana▼®

Tablet

02.05.05.02 Candesartan 

Tablets

13.09 Capasal ® 
13.05.02 Capasal Therapeutic Shampoo  
08.01.03 Capecitabine Xeloda®

Tablet

10.03.02 Capsaicin Qutenza®

capsaicin cream

02.05.05.01 Captopril 

Tablets

Restricted Item Oral Solution

04.08.01 Carbamazepine 

Syrup

Tablets

Modified Release tablets

06.02.02 Carbimazole 

Tablets

03.07 Carbocisteine 

Capsules, Liquid

11.08.01 Carbomers  

980 Eye Drops

980 Single-dose units

08.01.05 Carboplatin 

Injection

07.01.01 Carboprost 

Injection

08.01.05 Carfilzomib Kyprolis®

Powder for infusion

11.08.01 Carmellose Sodium  

0.5% Single dose unit

1% Single dose unit

11.08.01 Carmellose Sodium  

Single Dose Units 0.5%, 1%

08.01.01 Carmustine BiCNU®

Injection

08.01.01 Carmustine Gliadel®

implant

11.06 Carteolol Teoptic®

Eye Drops 1%

Eye Drops 2% 

02.04 Carvedilol 

Tablets

05.02.04 Caspofungin Cancidas®
07.04.04 Catheter Patency Solutions 

Chlorhexidine

 

Chlorhexidine Uro-Tainer 0.02%

07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 
13.02.02 Cavilon® Cream  
05.01.02.01 Cefalexin 

Capsules, Syrup, Tablets

restricted to indication. To be used in accordance with the local antibitic guidance and guidance from health protection agency

05.01.02.01 Cefixime 

Tablets

05.01.02.01 Cefotaxime 

Injection - for Meningitis and Neonatal Use Only

05.01.02.01 Ceftazidime 

Injection

05.01.02.01 Ceftobiprole 

Injection

05.01.02.01 Ceftriaxone 

Injection

GreenFor pelvic inflammatory disease

05.01.02.01 Cefuroxime 

Injection

11.03.01 Cefuroxime  

unlicensedunlicensed

5% Eye Drops

50mg Intra-cameral Injection

10.01.01 Celecoxib Celebrex®

Capsule
Cox-2 Inhibitor - osteoarthritis, rheumatoid arthritis Second line in patients unable to tolerate standard NSAID's.

 

02.04 Celiprolol Hydrochloride 
08.01 Cemiplimab Libtayo®

Infusion

08.01.05 Ceritinib Zykadia

Capsule

10.01.03 Certolizumab Pegol Cimzia®
03.04.01 Cetirizine 
13.02.01 Cetraben ® Lotion  
08.01.05 Cetuximab Erbitux®

Injection

08.01.01 Chlorambucil 

Tablet

05.01.07 Chloramphenicol 

Capsule, Injection

 

Microbiology Approval is required

11.03.01 Chloramphenicol 

Eye Drops 0.5%

Eye Ointment 1%

Minims 0.5%

04.01.02 Chlordiazepoxide 

capsule

11.03.02 Chlorhexidine 

unlicensedunlicensed

0.02% Eye Drops

05.04.01 Chloroquine 

   GreenTablet, Syrup
     

  Red Injection             

 

 

For the treatment of malaria. Should not be prescribed for malaria    prophylaxis on the NHS. Patients should obtain a supply on private prescription or purchase a supply "over the counter" as appropriate

02.02.01 Chlorothiazide 

Restricted Item  Suspension 250mg/5ml for paediatric use only. Available as an unlicensed product

03.04.01 Chlorphenamine 
04.02.01 Chlorpromazine 

Tablet, Oral solution, Suppository, Injection

06.05.01 Chorionic Gonadotrophin Pregnyl® Choragon®

Injection

01.05.03 Ciclosporin Neoral

Neoral 25mg, 50mg & 100mg  capsules

Neoral 100mg/ml  oral solution 50ml

Deximune 25mg, 50mg and 100mg capsules - to be used by dermatology only

08.02.02 Ciclosporin 

Capsules,

Oral, Solution

Red Injection

Red NHSE funded indication are usually Hospital Only

 

11.03.01 Ciclosporin 

Eye Drops 0.1%

11.04.02 Ciclosporin 

Eye Drops 1% (As per NICE TA369)

 

13.05.03 Ciclosporin 

Due to differences in bioavailability, patients must remain on the same brand of immunosuppressant.

01.03.01 Cimetidine 

Indication for painful bladder only

04.06 Cinnarizine 
05.01.12 Ciprofloxacin 

'Restricted by Indication'

 

Green Tablet, Suspension

 

Red  Injections 'prescribed in hospital only'

11.03.01 Ciprofloxacin 

Eye Drops 0.3%

08.01.05 Cisplatin 

Injection

04.03.03 Citalopram 

tablets

Oral Drops

01.06.05 Citramag ® 
08.01.03 Cladribine 

Infusion

08.01.03 Cladribine Mavenclad®

Tablet

05.01.05 Clarithromycin 

Injection, Tablets, Suspension, Sachets

05.01.05 Clarithromycin  Klaricid ®

for Lower repsirtory tract infections 

05.01.06 Clindamycin 

Use of Clindamycin is restricted by indication. Consult Antimicrobial Guidance before use

Green   Capsules

 

Red Traffic Light    Injection

Red Traffic Light   Suspension - Hospital Paediatric Use Only unlicensedunlicensed

07.02.02 Clindamycin Dalacin®

Used for bacterial vaginosis

04.08.01 Clobazam 

Tablets

Oral Suspension

13.04 Clobetasol propionate 0.05% 
13.04 Clobetasone butyrate 0.05% 
13.04 Clobetasone butyrate, Nystatin, Oxytetracycline calcium  Trimovate ®

 

 

08.01.03 Clofarabine Evoltra®

Intravenous infusion

06.05.01 Clomifene Citrate Clomid®

Tablet

04.03.01 Clomipramine 

Caspsule

04.02.03 Clonazepam 

tablets

02.05.02 Clonidine Catapres®

Tablets

Red Traffic Light Injection

04.07.04.02 Clonidine Hydrochloride 

Tablets

02.09 Clopidogrel 

Tablet

07.02.02 Clotrimazole 

Cream 2% - please consult antibiotic formulary advice

500mg pessaries (stat treatment)

 

 

Green 2 Canestan "Pessary Combi" for Primary care use only

04.02.01 Clozapine 

tablet

13.05.02 Coal Tar 10% Carbo-Dome®
02.02.04 Co-amilofruse (furosemide and amiloride) 

Tablet

05.01.01.03 Co-Amoxiclav 

Tablets, Dispersible Tablets, Suspension

 

To be prescribed in accordance with local antimicrobial guidance and guidance from health protection agency

05.01.01.03 Co-Amoxiclav 

Injection

04.09.01 Co-Beneldopa Madopar®CR

  Capsules

04.09.01 Co-Beneldopa Madopar®

(Benserazide/Levodopa) Capsules, MR Capsules, Dispersible tablets

05.03.01 Cobicistat Tybost®

Tablet

11.07 Cocaine 

Eye Drops 4%, 10ml

04.09.01 Co-Careldopa Half Sinemet ®CR

(Carbidopa/Levodopa) Tablets, MR Tablets

04.09.01 Co-Careldopa and Entacapone 

Tablets

13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
01.06.02 Co-danthrusate 

Capsules

To be used to treat terminally ill patients only

04.07.02 Codeine 

Tablets

03.09.01 Codeine Linctus  
01.04.02 Codeine Phosphate 

Tablets

04.07.02 Codeine Phosphate 
10.01.04 Colchicine 

tablets

01.09.02 Colesevelam 

625mg Tablets

02.12 Colestyramine 

Sachets

01.09.02 Colestyramine powder 
05.01.07 Colistimethate ® colomycin

Injection
Microbiologist approval required in all cases

05.01.07 Colistimethate for nebulisation Colobreathe®

Capsule - dry powder for inhalation
For the management of chronic pulmonary infections caused by P.aeruginosa in patients with cystic fibrosis (CF)

05.01.07 Colistimethate for nebulisation Promixin®

Nebule
"Restricted by Indication"

10.03.01 Collagenase Xiapex®

Injection

01.01.01 Co-magaldrox Maalox®

Use with caution in severe renal impairment as aluminium and magnesium may accumulate.

Suitable for patients with hepatic or cardiac failure, as it has low sodium content and is sugar free.

06.04.01.01 Combined continuous HRT tablet Kliofem, Kliovance, Femoston Conti, Premique

Kliofem® tablet (estradiol/Norethisterone)- no bleed

06.04.01.01 Combined cyclical HRT patch Evorel® Sequi, Evorel® Conti

Transdermal patch
20micrograms, 50micrograms, 75micrograms & 100micrograms

07.03.01 Combined Hormonal Contraceptives Microgynon 30 ED®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

07.03.01 Combined Hormonal Contraceptives TriNovum®

Ethinylestradiol 35micrograms and Norethisterone 500 micrograms, 750 micrograms and 1000micrograms.

07.03.01 Combined Hormonal Contraceptives Femodene® ED

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

03.04.03 Conestat Alfa Ruconest®

For the treatment of hereditary angioedema in the emergency care setting. 

06.04.01.01 Conjugated Oestrogen tablet Elleste-Solo, Premarin

Conjugated Oestrogens ( Premarin)  0.625mg, 1,25mg tablets

13.02.02 Conotrane® 
05.01.08 Co-trimoxazole Septrin®

Green  Tablet 480mg, Suspension

 

Red  Injection

13.08.02 Covermark ® 

ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo)  

08.01.05 Crisantaspase Erwinase®
08.01.05 Crizotinib Xalkori®

Capsule

13.03 Crotamiton Eurax®
04.06 Cyclizine Valoid®

Tablets

Injection

11.05 Cyclopentolate  

Eye Drops 0.5%

Eye Drops 1%

Minims 0.5%

Minims 1%

08.01.01 Cyclophosphamide 

Tablet, Injection

08.03.04.02 Cyproterone 

Tablet

06.04.02 Cyproterone Acetate 

Tablets

08.01.03 Cytarabine DepoCyte®

lipid formulation for intrathecal use

02.08.02 Dabigatran Pradaxa®

Capsules

08.01.05 Dabrafenib Tafinlar®

capsule

08.01.05 Dacarbazine 

Injection

05.03.03.02 Daclatasvir  Daklinza®

Tablet

08.02.02 Daclizumab Zenapax®
08.01.05 Dacomitinib Vizimpro®)

Tablet

08.01.02 Dactinomycin Cosmegen Lyovac®

injection

06.07.02 Danazol Danol®

Capsules

10.02.02 Dantrolene 

capsules

06.01.02.03 Dapagliflozin Forxiga▼®

Tablet

05.01.10 Dapsone 

tablet

05.01.07 Daptomycin 

Injection

Microbiology approval required

08.02.04 Daratumumab  (Darzalex®)

Solution for infusion

05.03.03.02 Dasabuvir Exviera®

Tablet

08.01.05 Dasatinib Sprycel®

Tablet

Powder for oral Suspension

08.01.02 Daunorubicin DaunoXome®

injection

08.01.02 Daunorubicin 44mg and Cytarabine 100mg Vyxeos®

Injection

08.03.04.02 Degarelix Firmagon®

injection

05.01.03 Demeclocycline 

Capsules

Restricted ItemLimited clinical use in context of antibiotic. Sometimes indicated for endocrine indications such as SIADH. Hence warranting restrited use

06.06.02 Denosumab XGEVA®

70mg/ml Injection

06.06.02 Denosumab Prolia®

60mg/ml Injection

13.08.02 Dermacolor ® 

ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo)  

06.05.02 Desmopressin 

Tablets 200 micrograms

Green For nocturnal enuresis,

 

Any pituitary condition the status should be designated as amber- please refer to chapter 7 for enuresis indication

06.05.02 Desmopressin DDAVP® Octim®

Injection 4 micrograms/ml, 1ml & 15 micrograms/ml, 1ml

06.05.02 Desmopressin 

Sublingual tablets

06.05.02 Desmopressin Desmospray®

Nasal spray 10 micrograms/dose, 5ml

07.03.02.01 Desogestrel Cerazette®, Cerelle®

Tablet

06.03.02 Dexamethasone 

Tablets
Injection 4mg/ml 2ml
Dexamethasone elixir 2mg/5ml

10.01.02.02 Dexamethasone 
11.04.01 Dexamethasone  

Eye Drops

Amber Traffic Light  0.1 Single Dose Eye Drops Preservative Free

Red Traffic Light  700mcg Intravitreal Impant (as per NICE TA301)

11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®

Eye Drops

Eye Ointment

04.04 Dexamfetamine 
04.07.02 Diamorphine 

 Tablets, Injection

 

Red Diamorphine hydrochloride (Ayendi ) 720microgram/actuation Nasal Spray, CD

 

*Please see information regarding current shortage: Patient Information *Patient information – diamorphine *

 

Further information regarding Diamorphine Shortage (mainly applicable for Secondary Care prescribing)
Unfortunately Accord have advised that there has been a further delay to their resupply date for diamorphine 5mg and 10mg injection and they are now expecting stock to be available during the week commencing 10th September. Wockhardt’s position remains unchanged, so please can all hospitals continue with current management plans as per previous communications in email chain below until the middle of September. There have been no changes to the supply position for the alternatives, so please refer to below communication for information about this.
We will communicate further information about the recovery plan in early September.

 

 

04.01.02 Diazepam 

Tablets
Oral solution


Diazepam is a high risk injectable medicine as identified by the NPSA patient safety alert 20

04.08.02 Diazepam epilepsy

Injection
emulsion injection 10mg/2ml

 

Diazepam is a high risk injectable medicine as identified by the NPSA patient safety alert 20

04.08.03 Diazepam 

rectal tubes

10.02.02 Diazepam 

Oral solution, tablets

04.08.02 Diazepam Rectal tubes  

Rectal Tubes

06.01.04 Diazoxide 

50 mg Tablet, oral solution (250mg/5mL)

Approved indications:

Insulinoma and tumour induced hypoglycaemia

Post gastric bypass hypoglycaemia causing syncope 

10.01.01 Diclofenac  

Tablets

10.01.01 Diclofenac 

Suppositories
Injection

Not recommended as a first line NSAID of choice due to small cardiac risks with diclofenac

10.03.02 Diclofenac 

Diclofenac Sodium Gel 1.16%.

11.08.02 Diclofenac Sodium Voltarol® Ophtha

0.1% Single Dose Units

05.03.01 Didanosine Videx®

Tablet

Capsule

05.05.06 Diethylcarbamazine 

unlicensed unlicensed

 

Tablets

02.01.01 Digoxin 

Bioavailabilites are approximately: Injection 100%, Liquid 80%, Tablets 70%.

 

Red Traffic Light Digoxin 500micrograms/ml injection

Red Traffic Light Digoxin 100micrograms/ml injection. Hospital, Paediatrics Only (SP)

04.07.02 Dihydrocodeine 

Tablets

 

Red Injection

Amber oral Liquid

05.04.02 Diloxanide 
02.06.02 Diltiazem 

Diltiazem MR (12hour) Tablets, Capsules. Prescribe by brand

Diltiazem XL (24 hour) Capsules. Prescribe by brand

01.07.04 Diltiazem Cream 2% 

cream

08.02.04 Dimethyl fumarate Tecfidera®
07.01.01 Dinoprostone 

Injection
MR pessaries (Propess)
Vaginal gel

1st choice for induction of labour as per NLAG  induction guidelines

 

08.02.04 Dinutuximab  (Qarziba®)
13.09 Diprosone® 0.05% Lotion  
02.09 Dipyridamole and Aspirin 

Modified Release Capsule

02.09 Dipyridamole MR 

Capsule

Amber Traffic Light Dipyridamole Suspension

Red Traffic Light Dipyridamole injection

11.09 Disodium Edetate 

unlicensedunlicensed

0.37% Solution 20ml

4% Solution 200ml

06.06.02 Disodium Etidronate Didronel PMO®

200mg Tablets

06.06.02 Disodium Pamidronate 

Injection 15mg, 90mg vial. Hospital Only

02.03.02 Disopyramide 

capsules

MR tablets

04.10.01 Disulfiram Antabuse®

to be initiated  and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service

13.05.02 Dithranol Cream  
13.05.02 Dithranol Paste  
02.07.01 Dobutamine 

injection

08.01.05 Docetaxel Taxotere®

Injection

01.06.02 Docusate Sodium 

Capsules
Oral Solution

05.03.01 Dolutegravir tivicay ®

Tablet

05.03.01 Dolutegravir, abacavir & lamivudine Triumeq®

Tablet

04.06 Domperidone 

Tablets

04.11 Donepezil Aricept®

Usually commenced by memory specialist then followed by GP

02.07.01 Dopamine 

injection

02.07.01 Dopexamine 

10mg/ml injection

03.07 Dornase Alfa 
11.06 Dorzolomide 

Eye Drops 2%

11.06 Dorzolomide 2% with Timolol 0.5% 

Dorzolomide 2%, Timolol 0.5% Eye Drops

04.03.01 Dosulepin 

tablet

Capsule

13.02.01 DoubleBase ® gel 
03.05.01 Doxapram Dopram®
02.05.04 Doxazosin 

Tablets

07.04.01 Doxazosin 

Tablet

08.01.02 Doxorubicin 

Injection

08.01.02 Doxorubicin Caelyx®

Concentrate for intravenous infusion

05.01.03 Doxycycline 

Capsules

Dispersible Tablets

02.03.02 Dronedarone Multaq®

Tablets

06.01.02.03 Dulaglutide  Trulicity ®

Injection

To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation.

04.03.04 Duloxetine Cymbalta®
08.02.04 Durvalumab   (Imfinzi® )

concentrate for solution for infusion

06.04.02 Dutasteride Avodart®

Capsules

06.04.01.02 Dydrogesterone 

Tablets

02.08.02 Edoxaban Lixiana®

Tablets

Edoxaban is the preferred DOAC for stroke prevention in NVAF, please consult the DOAC guideline below

10.02.01 Edrophonium Chloride 
05.03.01 Efavirenz Sustiva®

Capsule, Tablet

13.09 Eflornithine Vaniqa®
05.03.03.02 Elbasvir/Grazoprevir Zepatier®
01.04.02 Eluxadoline 

Tablet

 

To be used in Accordance with NICE TA 471

13.02.01.01 Emollient bath and shower preparations  
  • Bath and shower preparations for dry and pruritic skin conditions are now included in the guidance for items which should not routinely be prescribed in primary care by NHS England.
  • The BATHE trial showed that there was no evidence of clinical benefit for including emollient bath additives in the standard management of childhood eczema.
  • Soap avoidance and ‘Leave-on’ emollient moisturisers can still be used for treating eczema. These emollients can also be used as a soap substitute.
  • Patients should be counselled on the use of any emollients as soap substitutes and the risks of using bath and shower emollients should be fully explained
06.01.02.03 Empagliflozin Jardiance▼®

Tablet

05.03.01 Emtricitabine Emtriva®

Capsule, Oral Solution

05.03.01 Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera®

Tablet

13.02.01 Emulsifying ointment  
02.05.05.01 Enalapril  

Tablets

02.01.02 Enoximone Perfan®
04.09.01 Entacapone Comtess®
05.03.03.01 Entecavir Baraclude®

Tablet
Use in accordance with NICE guidance  

08.03.04.02 Enzalutamide Xtandi®

capsule

02.07.02 Ephedrine 

injection

13.02.01 Epimax ® 
08.01.02 Epirubicin 

Injection

02.02.03 Eplerenone 

Tablet

Restricted Item 

SECOND CHOICE

Second line aldosterone antagonist if spironolactone is not tolerated for NYHA class II heart failure

Second Line agent if Spironolactone is not tolerated for use within the licenced indication, of stable post MI patient with left ventricular dysfunction and clinical evidence of heart failure in line with NICE guidance.

 

02.09 Eptifibatide Integrilin®

INJECTION

07.01.01 Ergometrine Maleate 

500micrograms/ml Injection

07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®

Injection

04.07.04.01 Ergotamine Tartrate 

Tablets

08.01.05 Eribulin Halaven®

Injection

08.01.05 Erlotinib Tarceva®

Tablets

08.01.05 Erlotinib Tarceva®

Tablets

05.01.02.02 Ertapenem 

solution for infusion

Microbiologist Approval required in all cases

06.01.02.03 Ertugliflozin Steglatro®

Tablets

05.01.05 Erythromycin 

Talets

Use in pregnancy or if there is a known intolerance to clarithromycin

 

 

05.01.05 Erythromycin 

Lactobionate Injection - Hospital Only - GI motility agent only 

05.01.05 Erythromycin 

Erythromycin ethyl succinate mixture

13.06.01 Erythromycin 40mg/ Zine acetate 12mg/mL topical solution  Zineryt®
04.03.03 Escitalopram Cipralex®

Tablets

02.04 Esmolol 

Injection/Infusion

01.03.05 Esomeprazole 

Tablets

06.04.01.01 Estradiol with Noresthisterone  

Elleste-Duet®- tablet 1mg and 2mg
Femoston 1/10 and 2/10 tablet

08.01.01 Estramustine Phosphate Estracyt®
10.01.03 Etanercept Benepali®

subcutaneous injection

10.01.03 Etanercept Enbrel®

subcutaneous injection

13.05.03 Etanercept 
05.01.09 Ethambutol  

tablet

unlicensed unlicensed  - Ethambutol Liquid. Consultant Paediatrician Only (unlicenced & specials)

06.04.01.01 Ethinylestradiol 

Red2microgram tablets Secondary care, Paediatrician initiated only

Green 10micrograms, 50micrograms, 1mg tablets

07.03.01 Ethinylestradiol / levonorgestrel phased pill  Logynon®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg Yasmin®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

07.03.01 Ethinylestradiol 30 mcg / levonorgestrel 150 mcg Ovranette® Rigevidon®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique®

Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.

Can be prescribed for outpatient clinics for secondary care

04.08.01 Ethosuximide 

Oral Solution

07.03.02.02 Etonorgestrel Implanon®

68mg Implant (Nexplanon). Primary Care & Sexual Health Only

08.01.04 Etoposide Etopophos®

Capsule, Infusion

05.03.01 Etravirine Intelence®

Tablet

08.01.05 Everolimus Votubia®

Tablet

Dispersible tablet

08.01.05 Everolimus Afinitor®

Tablets

02.14 Evolocumab Repatha®

Subcutaneous Injection

08.03.04.01 Exemestane 

Tablets 25mg

06.01.02.03 Exenatide prolonged release Bydureon▼®

Injection m/r
Bydureon= once weekly formulation

To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation

02.12 Ezetimibe Ezetrol®

To be used in accordance with associated NICE technical appraisal

02.11 Factor VIIa (Recombinant) Novo 7®
05.03.02.01 Famciclovir Famvir®

Tablet

06.01.01.01 Fast Acting Insulin Aspart  Fiasp®

Injection

Must be initiated by specialist only.

To be prescribed by brand only

10.01.04 Febuxostat Adenuric®

tablets

04.07.02 Fentanyl Instanyl® nasal spray

Nasal Spray – Lindsey Lodge Hospice Only CD

04.07.02 Fentanyl 

Injection

04.07.02 Fentanyl 

Patches

04.07.02 Fentanyl Nasal Spray PecFent®
04.07.02 Fentanyl sublingual tablets Abstral®

Sublingual Tablets

03.04.01 Fexofenadine 
11.08.02 Fibrin Sealant Tisseel
05.01.07 Fidaxomicin 

200mg Tablets - Requires Microbiologist authorisation 

Suitable for Primary care to prescribe provided there is authorisation from a microbiologist

05.01.07 Fidaxomicin Dificlir®
06.04.02 Finasteride 

Tablets

08.02.04 Fingolimod 
02.03.02 Flecainide 

Tablet and Syrup

 

 

01.06.05 Fleet Phospho-soda ® 

Oral Solution

05.01.01.02 Flucloxacillin 

Injection

05.01.01.02 Flucloxacillin 

Capsules

Syrup

05.02 Fluconazole 

Injection, Infusion

05.02 Fluconazole Diflucan®

Capsule, Suspension

07.02.02 Fluconazole 

Tablet, Capsule

08.01.03 Fludarabine Phosphate Fludara®

Tablet, Injection

06.03.01 Fludrocortisone 

Tablets

 

Amber if prescribed for postural hypotension

11.04.01 Fluocinolone intravitreal implant Iluvien®

As per NICE TA301

11.08.02 Fluorescein 

1% Minims

2% Minims

Red Traffic Light  20 Injections (Hospital Consultant Only)

11.04.01 Fluorometholone FML®

Eye Drops 0.1%

08.01.03 Fluorouracil 
08.01.03 Fluorouracil 

cream

For dermatology indications

04.03.03 Fluoxetine 

Capsules

04.02.01 Flupentixol Depixol®

tablet

04.02.02 Flupentixol Decanoate Depixol®

Depot Injection 

04.02.02 Flupentixol Decanoate Depixol® Conc.

Depot Injection 

04.02.02 Fluphenazine Decanoate 

depot injection

08.03.04.02 Flutamide 

Tablets

03.02 Fluticasone furoate & vilanterol Relvar Ellipta®
03.02 Fluticasone furoate, umeclidinium & vilanterol (as trifenatate) trelegy ®

 

Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder (pre-dispensed) contains the following:

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent to 62.5 micrograms umeclidinium and 25 micrograms vilanterol (as trifenatate).

03.02 Fluticasone propionate and formoterol Flutiform®

children between 12-18 where sirdupla is not licenced

03.02 Fluticasone propionate and salmeterol AirFluSal Forspiro®
03.02 Fluticasone propionate and salmeterol Sirdupla®, Seretide®

Green Restricted ItemSeretide 50 Evohaler * Paediatric use only

Amber Seretide Evohaler and Accuhaler.
Restricted to use in asthma not to be used as new initiation for COPD   

02.08.01 Fondaparinux Arixtra®

For Acute Coronary Syndrome

03.01.01.01 Formoterol  

Turbohaler

  • Long-acting beta-agonist
  • Formoterol Easyhaler® preferred as more cost effective
05.03.01 Fosamprenavir Telzir®

Tablet, Oral Suspension

05.01.07 Fosfomycin 

Green  3g Oral Sachets

Not be used first line and must be used in accordance with culture and sensitivity results.

For treatment resistant UTI licenced for women, doses change as per gender

 

Red  Injection ( unlicensedUnlicensed )

08.03.04.01 Fulvestrant Faslodex®

Injection

02.02.02 Furosemide 

Red Traffic Light Injection.  IV doses of 40mg or 80mg can be slow bolused. Larger doses must be infused at a max rate of 4mg/min

 

11.03.01 Fusidic Acid 

Eye Drops 1%

04.08.01 Gabapentin 

Capsules

 

From April 2019 gabapentin will be reclassified as class C controlled substance. Prescriptions will need to be physically signed by doctors; electronic copies will not be accepted by pharmacists - the total quantity will need to be written on the prescription in both words and figures and pharmacists will need to dispense the drugs within 28 days of the prescription being written

04.11 Galantamine Galsya® XL

Tablet

Modified Release Capsules

05.03.02.02 Ganciclovir Cymevene®

Infusion

11.03.03 Ganciclovir 0.15% ophthalmic gel Virgan®
01.01.02 Gastrocote 

Tablets

01.01.02 Gaviscon Infant ® 

Oral Powder

For peadiatric use only

08.01.05 Gefitinib Iressa®

Tablet

08.01.03 Gemcitabine Gemzar®

injection

08.02.03 Gemtuzumab ozogamicin  

injection

05.01.04 Gentamicin 

Injection

11.03.01 Gentamicin 

Eye Drops 0.3%

11.03.01 Gentamicin 

unlicensedunlicensed

1.5% Eye Drops

06.07.02 Gestrinone 

Capsules 2.5mg

08.02.04 Glatiramer Acetate Copaxone®

injection

05.03.03.02 Glecaprevir and Pibrentasvir Maviret®

Tablet

06.01.02.01 Gliclazide 

Tablets, Modified release tablets

Non modified release formulation are first choice

06.01.04 Glucagon GlucaGen® HypoKit

Injection, Tablets , Drink ( e.g. lucozade drink) 

06.01.04 GlucoGel ® 

Dextrose Gel,

 

06.01.06 Glucose Monitoring System  FreeStyle Libre ®

FreeStyle Libre® is a flash glucose monitoring (Flash GM) system which monitors glucose levels using interstitial fluid levels rather than capillary blood glucose from finger prick testing

All prescribing of freestyle libre should be carried out in line with the agreed prescribing statement below

https://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2019/08/Prescribing-Arrangements-for-Flash-Glucose-Monitoring-Final-2.pdf

11.06 Glycerin  

50% Eye Drops unlicensedunlicensed

BP Syrup, licensed

11.06 Glycerin 

50% Eye Drops unlicensedunlicensed

BP Syrup, licensed

01.06.02 Glycerol 

suppositories

02.06.01 Glyceryl Trinitrate 

Available as S/L Tablet, Spray

Red Traffic Light Injection

Red Traffic Light  Restricted Item Patches

01.07.04 Glyceryl Trinitrate 0.4% 

Ointment

07.04.04 Glycine 

Irrigation solution 1.5%

03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®
03.01.02 Glycopyrronium Seebri breezhaler®
01.05.03 Golimumab 

to be used in accordance with NICE TA329

10.01.03 Golimumab Simponi®
06.05.01 Gonadorelin HRF®

Injection

06.07.02 Goserelin Zoladex®

 Injection
Injection 3.6mg, 10.8mg.

08.03.04.01 Goserelin Zoladex®

Injection 3.6mg, 10.8mg

08.03.04.02 Goserelin Zoladex®

3.6mg  Injection

08.03.04.02 Goserelin Zoladex® LA

10.8mg Injection

04.06 Granisetron 

Injection

Tablets

 

Consultant Initiated Only and Restricted Hospice Use

04.06 Granisetron transdermal patch Sancuso®

Patches

 

Consultant Initiated Only and Restricted Hospice Use

03.04.02 Grass and Tree Pollen Extract Pollinex®

Subcutaneous Injection by Immunologist Only

02.05.03 Guanethidine Monosulphate Ismelin®

injection

04.02.01 Haloperidol 

Capsule
Tablet
Oral liquid

haloperidol solution for injection

04.02.02 Haloperidol Haldol Decanoate®

Depot Injection 

02.08.01 Heparin 

Injection

02.08.01 Heparin 

Flush Injection

11.05 Homatropine 

Minims 2%

10.01 Hyaluronic acid Hyalgan®
10.03.01 Hyaluronidase Hyalase®
02.05.01 Hydralazine 

Tablets

Red Traffic Light Injection

01.05.02 Hydrocortisone  Colifoam®

Foam Enema

Colifoam

06.03.02 Hydrocortisone 

10mg tablets, 20mg tablets

06.03.02 Hydrocortisone 

Suspension 5mg/5ml
Paediatrician Initiated Only

11.04.01 Hydrocortisone  

Eye Ointment 2.5%

13.04 Hydrocortisone  
06.03.02 Hydrocortisone acetate 

Injection 100mg

10.01.02.02 Hydrocortisone acetate Hydrocortistab®
13.04 Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone®
13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®
13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®
13.02.01 Hydrous ointment  
08.01.05 Hydroxycarbamide 

Capsule

10.01.03 Hydroxychloroquine 

tablet

11.08.01 Hydroxypropyl Guar Systane®

Ultra

Ultra UD

Balance

Gel

01.02 Hyoscine Butylbromide 

Tablets,

GreenInjection - only green for use in Palliative care only

04.06 Hyoscine Hydrobromide 

Tablets

Patches

 

11.08.01 Hypromellose 

0.3% Eye Drops

0.5% Eye Drops

1% Eye Drops

11.08.01 Hypromellose 0.3% with Dextran 70 0.1% 

Hypromellose 0.3% with Dextran 70 0.1% Eye Drops

06.06.02 Ibandronic Acid 

150mg Tablets

06.06.02 Ibandronic Acid 

50mg Tablets. Hospital Initiated

See HYCCN Guidelines

06.06.02 Ibandronic Acid injection 

3mg Injection Post-menopausal Osteoporosis

08.01.05 Ibrutinib Imbruvica®

Capsule, Tablet

10.01.01 Ibuprofen 

Tablet, Suspension

10.03.02 Ibuprofen gel 

topical gel

03.04.03 Icatibant Firazyr®

For the treatment of hereditary angioedema in the emergency care setting. 

13.05.01 Ichthammol 
13.05.01 Ichthammol 
08.01.02 Idarubicin Zavedos®

Capsule, injection

02.08 Idarucizumab Praxbind®

Injection. For reversal of dabigatran anticoagulation only. Not suitable for Anti Xa Agents

08.01.05 Idelalisib Zydelig®

Not recommended for use by NICE in NICE TA604

08.01.01 Ifosfamide Mitoxana®
02.05.01 Iloprost injection  
08.01.05 Imatinib Gilvec®

tablet

05.01.02.02 Imipenem with Cilastatin 

Injection

Group 3 restricted.

Microbiology approval is required in all cases

04.03.01 Imipramine 

tablet

08.02.04 Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) (Kymriah®)
02.02.01 Indapamide 

2.5mg Tablets

11.08.02 Indocyanine Green Dye 
10.01.01 Indometacin 

Capsules, MR Capsules

02.05.04 Indoramin 

Tablets

01.05.03 Infliximab 
10.01.03 Infliximab Remicade®
13.05.03 Infliximab 
08.01 Inotuzumab ozogamicin Besponsa®

infusion

06.01.01.01 Insulin Humulin® S

Vial, KwikPen, 3mL cartridge, 100unils/mL

06.01.01.01 Insulin Actrapid®

Vial

100units/mL

06.01.01.01 Insulin 500 units in 1mL Humulin R®

unlicensed unlicensed product

Named patient only

06.01.01.01 Insulin Aspart  NovoRapid®

Vial, Cartridge, Pre-filled pen (FlexPen, FlexTouch)

06.01.01.02 Insulin degludec Tresiba®

In light of adhering towards the integrated Diabetes pathway the AMBER status only applies if the Diabetologist has provided a written confirmation ( via email/ or letter etc) to a General Practitioner stating the appropriateness of initiating the prescribing of Tresiba. 

General Practitioner are therefore permitted to prescribe this medication provided that the suitability of initiating this product must be identified by a specialist/ diabetologist.

06.01.02.03 Insulin degludec and liraglutide Xultophy®

Pre-filled pen

 

06.01.01.02 Insulin Detemir Levemir®

Cartridge, Prefilled pen (FlexPen, InnoLet)
Long-acting insulin analogues (LAIAs) have no advantages over human isophane insulin in effects on HbA1c levels. 

06.01.01.02 Insulin Glargine Lantus®

Vial, Cartridge for ClikSTAR
Prefilled pen - Solostar®
Long-acting insulin analogues (LAIAs)

06.01.01.02 Insulin Glargine Toujeo®

In light of adhering towards the integrated Diabetes pathway the AMBER status only applies if the Diabetologist has provided a written confirmation ( via email/ or letter etc) to a General Practitioner stating the appropriateness of initiating the prescribing of Toujeo. 

General Practitioner are therefore permitted to prescribe this medication provided that the suitability of initiating this product must be identified by a specialist/ diabetologist.

06.01.01.02 Insulin Glargine biosimilar 

100 units/mL - Cartridge and KwikPen prefilled pen

06.01.01.01 Insulin Glulisine Apidra®

Vial, 3mL cartridge, solostar

06.01.01.01 Insulin Lispro  Humalog®

Vial, KwikPen, 3ml cartridge, 100units/mL

08.02.04 Interferon Alfa 
08.02.04 Interferon Alfa Roferon-A®
08.02.04 Interferon Beta Avonex®

Injection

08.02.04 Interferon Beta Rebif®

injection

08.02.04 Interferon Beta Betaferon®

Injection

08.02.04 Interferon beta Extavia®
07.03.02.03 Intra-uterine Progestogen Only System Mirena®

Intra-uterine system

06.02.02 Iodine and Iodide 

Aqueous Iodine BP Syn:Lugol's solution

08.01.05 Ipilimumab Yervoy®

Concentrate for intravenous infusion

03.01.02 Ipratropium Bromide 

Short-acting antimuscarinic
Inhaler, Nebules
Should only be prescribed for those patients with COPD in whom salbutamol is not tolerated or ineffective. It should not be used in combination with salbutamol.
For those patients requiring regular antimuscarinuc therapy tiotropium is the prefered choice

02.05.05.02 Irbesartan 

Tablets

08.01.05 Irinotecan Hydrochloride 

Infusion

05.01.09 Isoniazid 

Tablet, Injection
Elixir 50mg/5ml - Unlicensed

06.01.01.02 Isophane Insulin Insulatard®

Vial, Cartridge, Prefilled InnoLet

06.01.01.02 Isophane Insulin Humulin® I

Vial, Cartridge, Prefilled pen (KwikPen)

02.06.01 Isosorbide Dinitrate Injection- Isoket®
02.06.01 Isosorbide Mononitrate 

Tablets

including Long acting, once daily preparation

13.06.01 Isotretinoin 
01.06.01 Ispaghula Husk 

Granules

05.02 Itraconazole 

Capsules, Liquid

02.06.03 Ivabradine 

Tablets

Specialist Initation only for two indications :

1) Angina

Cardiology specialist initiation only in line with NICE Clinical Guidance on stable angina for patients who remain symptomatic despite maximal doses of other anti-anginal medication. 

 

2) Heart Failure

In line with NICE TA 267.  Ivabradine is an option for treating people with chronic heart failure who meet the following criteria :

- with NYHA class II to IV stable chronic heart failure with systolic dysfunction and
- who are in sinus rhythm with a heart rate of 75 bpm or more and
- who are given ivabradine in combination with standard therapy including beta-blocker therapy, ACE inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and
- with a left ventricular ejection fraction of 35% or less.

05.05.06 Ivermectin 

unlicensed unlicensed

Tablets

13.06 Ivermectin cream Soolantra®
08.01.05 Ixazomib Ninlaro®

Capsule

13.05.03 Ixekizumab 
13.08.02 Keromask ® 

ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo)  

05.02 Ketoconazole Nizoral®

Shampoo

11.08.02 Ketorolac Trometamol  

Eye Drops 0.5%

03.04.01 Ketotifen 
01.06.05 Klean-Prep ® 

KleanPrep Vanilla for Patients sensitive to citrus Flavourings and paediatrics

02.04 Labetalol 

Tablets

Red Traffic Light Injection

04.08.01 Lacosamide  Vimpat ®

Tablets

RedSolution for infusion

01.06.04 Lactulose 

Liquid

05.03.01 Lamivudine Epivir®

Tablet
Oral Solution

05.03.01 Lamivudine Zeffix®

Tablet

04.02.03 Lamotrigine 

Tablets

Dispersible Tablets

03.04.03 Lanadelumab 
08.03.04.03 Lanreotide 

Injection - Prefilled syringe

01.03.05 Lansoprazole 

Capsules

Restricted ItemOrodispersible tablets  restricted for use in patients with swallowing difficulties or who are on enteral tube feeding.

11.06 Latanoprost 

Eye Drops 50mcg/ml (UDVs for Preservative Sensitivity)

11.06 Latanoprost 0.005% with Timolol 0.5% 

Latanoprost 50mcg, Timolol 5mg/ml

05.03.03.02 Ledipasvir and Sofosbuvir Harvoni®

Tablet

10.01.03 Leflunomide 

Tablet

08.02.04 Lenalidomide 

Capsule

08.01.05 Lenvatinib Lenvima® and Kisplyx®

Capsule

To be prescribed by brand

02.08.01 Lepirudin 
02.06.02 Lercanidipine 
05.03.02.02 Letermovir  
08.03.04.01 Letrozole 

Tablet

06.07.02 Leuprorelin  Prostap®

Injection 3.75mg, 11.25mg

08.03.04.02 Leuprorelin Acetate Prostap® SR

3.75mg Injection

08.03.04.02 Leuprorelin Acetate Prostap® 3

11.25mg Injection

05.05.02 Levamisole 

unlicensed unlicensed

 

Unlicenced Tablet

04.08.01 Levetiracetam 

Tablets

Oral Solution

05.01.12 Levofloxacin 

Tablet

Restricted Item Levofloxacin Infusion 500mg/100ml  restricted use only

13.03 Levomenthol  Menthoderm®, Dermacool®, Arjun

Licensed products should be used where possible

04.06 Levomepromazine 

Tablet

Injection

07.03.05 Levonogrestrel Levonelle® 1500

Tablets

06.02.01 Levothyroxine 

Tablets

02.03.02 Lidocaine 

injection

11.07 Lidocaine hydrochloride 4%, Fluorescein Sodium 0.25% 

Lidocaine hydrochloride 4%, Fluorescein Sodium 0.25% Minims

01.06.07 Linaclotide Constella®

Consultant Initiation only  as per constipation pathway

06.01.02.03 Linagliptin Trajenta▼®

DPP-4 inhibitor approved for use in patients with severe renal or hepatic impairment

05.01.07 Linezolid 

Tablet, Injection
Microbiologist approval required in all cases

06.02.01 Liothyronine 

Tablets, Injection

06.01.02.03 Liraglutide Victoza®

Injection

To be used in accordance with Diabetespathway.  Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation.

04.04 Lisdexamfetamine Elvanse®

Capsules

02.05.05.01 Lisinopril 

Tablets

04.02.03 Lithium Carbonate Liskonum®

Tablet MR

04.02.03 Lithium Carbonate  Essential Pharma

Tablet MR

 

04.02.03 Lithium Carbonate Priadel®

Tablet MR

04.02.03 Lithium Citrate Priadel®

liquid

Liquid 520mg (approx 5.4mmol Li+) in 5ml.

06.01.02.03 Lixisenatide Lyxumia▼®

Injection

For use as an adjunct to existing oral hypoglycaemic and/or insulin therapy in type 2 diabetes mellitus (DM) where glycaemic control is inadequate

To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation

04.03.01 Lofepramine 

Tablet,

Oral Solution

08.01.01 Lomustine 
01.04.02 Loperamide 

capsules

Red syrup

Amber immodium instant melts for stoma patients only

05.03.01 Lopinavir and Ritonavir Kaletra®

Tablet
Liquid

03.04.01 Loratadine 
04.01.02 Lorazepam 

tablets

04.08.02 Lorazepam 

Injection

02.05.05.02 Losartan 

Tablet

11.04.01 Loteprednol 

Eye Drops 0.5%

01.06.07 Lubiprostone Amitiza®

To be used in accordance with NICE TA318

04.02.01 Lurasidone Latuda®

Tablet

For use in RDASH Only, but requires clinicians to complete a prior approval form before prescribing of the drug is considered

05.01.03 Lymecycline Tetralysal® 300

Capsules

13.06.02 Lymecycline capsules 408mg 
01.01.01 Maalox Plus 
01.06.04 Macrogol  

Sachets

01.06.05 Macrogols Moviprep®

Sachets

01.01.01 Magnesium Trisilicate 
02.02.05 Mannitol 

Hospital Only

11.06 Mannitol 

20% Infusion

03.07 Mannitol inhalation Bronchitol ®
05.03.01 Maraviroc Celsentri®

Tablet

Oral Solution

05.05.01 Mebendazole 

Tablets
Suspension

01.02 Mebeverine 
03.07 Mecysteine Visclair®

Tablets

06.04.01.02 Medroxyprogesterone Acetate Provera®

Tablets

07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®

150 mg/ml PFS. Primary Care & Sexual Health Only

08.03.02 Medroxyprogesterone Acetate Provera®

Tablet

Red injection

Red for treatment of oncology indications

10.01.01 Mefenamic Acid 
05.04.01 Mefloquine Lariam®
04.01.01 Melatonin  Circadin®

modified release tablet

04.01.01 Melatonin Paediatrics

unlicensed unlicensed  
Oral solution - unlicenced preparation
unlicensed unlicensed 
1mg/ml oral preparation (colonis) is NOT suitable for paediatric prescribing please refer to product characteristics for further information.

 


unlicensed unlicensed 
Standard release tabets -unlicenced preparation

10.01.01 Meloxicam 

Tablets

08.01.01 Melphalan 

tablet, Injection

04.11 Memantine Ebixa®

Tablet, orodispersible tablet and solution

05.04.04 Mepacrine Hydrochloride 
03.04.02 Mepolizumab Nucala®
01.05.03 Mercaptopurine 

Tablets

08.01.03 Mercaptopurine 

tablet, suspension

05.01.02.02 Meropenem 

Injection

Group 2 restricted due to 9 permitted indications.

To be used in accordance with antimicrobial guidance and health protection agency guidance

01.05.01 Mesalazine Octasa

Modified Release Tablets

Octasa is the first choice formulation for all newly diagnosed patients as it is more cost-effective than Asacol.

01.05.01 Mesalazine Asacol®

1g/ application foam enema, gastro-resistant tablet, suppository,

Restricted Itemnot first choice for commencing new patients on mesalazine.  Asacol is mainly reserved for patients who are stable on asacol formulations.

01.05.01 Mesalazine Pentasa®

modified release granules, modified release tablets, suppositories, enema

01.05.01 Mesalazine Salofalk®

Liquid enema, foam enema

01.05.01 Mesalazine  Mezavant® XL

Mezavant XL  ( Modified release tablets)  

08.01 Mesna 

Tablet, injection

02.07.02 Metaraminol 

Injection

06.01.02.02 Metformin Modified Release tablet® SR
06.01.02.02 Metformin 

Tablet, sachets, Oral Liquid

04.07.02 Methadone 

tablets

04.10.03 Methadone 

To be commenced by the specialist service only and prescribing must be in collaboration with the advice from the substance misuse services.

05.01.13 Methenamine Hippurate Hiprex®

Tablets – Following Urologist recommendation only

Features in Primary care document

01.05.03 Methotrexate 

2.5mg tablets

08.01.03 Methotrexate 

Injection

10.01.03 Methotrexate 

Tablets

 

10.01.03 Methotrexate Metoject®

Subcutaneous injecton is currently Hospital Only

04.07 Methoxyflurane Penthrox®

3ml +Inhaler + ac chamber

for use in Emergency Care Centres only

13.05.02 Methoxypsoralen  
01.06.01 Methycellulose 

Tablets

02.05.02 Methyldopa 

tablets

01.06.06 Methylnaltrexone Relistor®
04.04 Methylphenidate 

Prescribe generically, unless a brand is necessary

04.04 Methylphenidate Hydrochloride Equasym® XL

MR Capsules

Equasym XL,

Medikinet XL

04.04 Methylphenidate Hydrochloride Ritalin®

MR Tablets  

Concerta XL, Matoride XL, Xenidate XL

 

Note different release properties between each brand. Prescribe by brand where necessary. Specialist Initiated Only.

06.03.02 Methylprednisolone 

500mg injection
1g Vial

Methylprednisolone 100mg tablets, Rahabilitation services and Opthalmic surgery only

10.01.02.02 Methylprednisolone Acetate Depo-Medrone®

Injection 40mg in 1mL
Injection 80mg in 2mL

10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine
04.06 Metoclopramide 

Tablets

Red Injection

02.02.01 Metolazone 

Tablet was discontinued March 2012.

For patients in whom bendroflumethiazide is not suitable, an unlicensed import may be available for use by secondary care

 

02.04 Metoprolol 

Tablets

05.04.02 Metronidazole 

Green Tablet, Suspension, Suppository

 

Red Infusion

07.02.02 Metronidazole Zidoval®

Vaginal gel 0.75%

13.06 Metronidazole 0.75%  
06.07.03 Metyrapone Metopirone®
07.02.02 Miconazole Gyno-Daktarin®

Intravaginal cream

Vaginal capsule

04.08.02 Midazolam hydrochloride  

Injection.

Solution for injection/infusion

04.08.02 Midazolam Hydrochloride  Buccolam®

oromucosal solution

04.08.02 Midazolam Maleate  

10mg Oromucosal Solution

02.07.02 Midodrine 

Consultant initiation only when fludrocortisone ineffective for orthostatic hypotension.

08.01.05 Midostaurin Rydapt®

Capsule

08.02.04 Mifamurtide Mepact®

Intravenous Infusion

07.01.02 Mifepristone Mifegyne®

Tablet

To be used in adherence with the Termination of pregnancy guideline 

02.01.02 Milrinone  

Injection

02.05.01 Minoxidil 

Tablets

07.04.02 Mirabegron Betmiga®

Tablet m/r

04.03.04 Mirtazapine 

Tablet

Orodisperible tablet

Oral solution

01.03.04 Misoprostol 

Tablets

07.01.01 Misoprostol 

Tablets

08.01.02 Mitomycin 

Injection, bladder instillation

08.01.02 Mitoxantrone Onkotrone®

Infusion

08.01.02 Mitoxantrone (Mitozantrone) 

Infusion

04.03.02 Moclobemide 

Tablets

04.04 Modafinil Provigil®

Tablets

13.04 Mometasone furoate 0.1% 
03.03.02 Montelukast Singulair®
04.07.02 Morphine Salts 

Standard relase (~4 hours effect): Oral solution (e.g. Oramorph®), Tablet (Sevredol®)

Slow release (~12hr effect): Modified Release Capsule: Zormorph and Morphgesic SR. Modified release tablet: MST Continous® Tablet MR

Injection

Red Morphine Sulphate MR Sachets, Suppositories

 

05.01.12 Moxifloxacin 

Tablets

Injection

11.03.01 Moxifloxacin 

0.5% Eye Drops

02.05.02 Moxonidine 

Tablets

08.02.01 Mycophenolate Mofetil 
08.02.01 Mycophenolate Sodium Myfortic®
01.05.03 Mycophenolate Mofetil 

capsules

11.08.02 Mydricaine 

No 1 Injection

No 2 Injection

04.06 Nabilone 

Capsules

02.06.04 Naftidrofuryl 

Capsules

04.10.01 Nalmefene 

to be initiated  and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service

01.06.06 Naloxegol Moventig

To be used in accordance with NICE TA345 and the constipation pathway

 

04.10.03 Naltrexone Nalorex®

Tablets

To be prescribed and initiated by specialist service and can be continued to be prescribed under advice or recommendedation of specialist service

06.04.03 Nandrolone Deca-Durabolin®

injection

10.01.01 Naproxen 

Tablet

08.02.04 Natalizumab Tysabri®

injection

02.04 Nebivolol 

Restricted Item

03.03.01 Nedocromil Tilade® CFC-free inhaler
04.07.01 Nefopam 

Approved only for short-term use by specialist doctor/ consultant in ICU in patients with renal or liver impairment where NSAIDs are contraindicated.  

08.01.03 Nelarabine Atriance®

Intravenous Infusion

11.04.02 Neodocromil Rapitil®

Sodium Eye Drops 2%

05.01.04 Neomycin 

Tablets, Syrup

 

Specialist initiation only

10.02.01 Neostigmine 

injection
Tablets

11.04.02 Nepafenac 

0.1% Eye Drops

08.01.05 Neratinib 

Approved for use in line with NICE TA612

05.03.01 Nevirapine Viramune®

Tablet, Suspension, Tablet MR

02.06.03 Nicorandil 

Tablets

  • Not to be used as first-line treatment for angina in line with NICE and MHRA guidance.
  • See recent warnings regarding risk of serious skin, mucosal, and eye ulceration, which persists unless treatment is discontinued.

 

02.06.02 Nifedipine 

Capsules

Modified Release Tablets to be prescribed by Brand.

08.01.05 Nilotinib Tasigna®
02.06.02 Nimodipine Nimotop®

Tablets and Injection

03.11 Nintedanib Ofev®
08.01.05 Nintedanib Vargatef ®

Tablet

08.02.04 Niraparib (Zejula®)

Capsule

04.01.01 Nitrazepam 

tablets

05.01.13 Nitrofurantoin 

Tablets, Capsules, Modified Release Capsules,  Suspension

1st line for simple cystitis

08.02.04 Nivolumab Opdivo®
02.07.02 Noradrenaline / Norepinephrine 

injection

06.04.01.02 Norethisterone 

Tablets

07.03.02.01 Norethisterone 

Tablets

04.03.01 Nortriptyline 

Tablets

05.02 Nystatin Nystan®

Oral suspension 100 000 units per mL

01.09.01 Obeticholic acid Ocaliva®
08.02.03 Obinutuzumab Gazyvaro ®

infusion

08.02.03 Ocrelizumab Ocrevus®

Infusion

11.08.02 Ocriplasmin  

2.5mg/ml Intravitreal Injection

02.11 Octocog alfa sucrose plasma protein-free Iblias®
08.03.04.03 Octreotide Sandostatin®

injection

08.03.04.03 Octreotide Sandostatin Lar®

50 mcg/ml, 100 mcg/ml injection

06.04.01.01 Oestrogen only HRT gel estradiol Gel

Estradiol gel

06.04.01.01 Oestrogen only HRT implant Estradiol

50mg, 100mg Implants

 

06.04.01.01 Oestrogens for HRT Estradiol

Estradiol Tablets 1mg 2mg

06.04.01.01 Oestrogens for HRT Estraderm MX®

Estraderm MX 25, 50, 75

06.04.01.01 Oestrogens gel  Estradiol®

gel

07.02.01 Oestrogens, Topical 

Estriol Intra Vaginal Cream 0.01% Contains Arachis (peanut) Oil

Estriol Intra Vaginal Cream 0.1%

 

07.02.01 Oestrogens, Topical Vagifem®

Vaginal tablet: estradiol 10micrograms

08.02.03 Ofatumumab Arzerra®

Infusion

05.01.12 Ofloxacin 

Tablet
"Restricted by Indication" - see list in Antibiotic guidelines

Second line sometimes used for epididymitis/ orchitis as better tolerated

11.03.01 Ofloxacin Eye drops 

Eye Drops 0.3%

04.02.01 Olanzapine 

tablets

04.02.02 Olanzapine Embonate ZypAdhera®

depot Injection

08.02.04 Olaparib Lynparza®
08.01.05 Olaratumab Lartruvo®

Injection

03.01.01.01 Olodaterol Striverdi Respimat®
11.04.02 Olopatadine Opatanol®

Eye Drops 0.1%

01.05.01 Olsalazine 

tablets, capsules

03.04.02 Omalizumab 
05.03.03.02 Ombitasvir/ paritaprevir/ ritonavir Viekirax®

tablet

01.03.05 Omeprazole 

Capsules

 

Restricted Itemorodispersible tablets available for when the beads in the capsule are too large and lansoprazole orodispersible are not acceptable

RedInjection/ infusion

 

04.06 Ondansetron 

Tablets

Injection

07.03.02 Oral Progestogen-Only Contraceptives Femulen®

Tablet

04.05.01 Orlistat 

Capsules

05.03.04 Oseltamivir Tamiflu®

Capsule and suspension

To be used with Public health Guidance

08.02.04 Osimertinib Tagrisso
08.01.05 Oxaliplatin 

Injection

08.01.05 Oxaliplatin Eloxatin®
04.01.02 Oxazepam 

tablets

04.08.01 Oxcarbazepine Trileptal®

Tablets

11.07 Oxybuprocaine 

0.4% Minims

07.04.02 Oxybutynin 

Tablet
Tablet m/r

Restricted Item Information on restriction

Liquid restriced to indication and paediatric use

07.04.02 Oxybutynin Hydrochloride Kentera®

Patch

04.07.02 Oxycodone 

Liquid

MR Tablets

Capsules

Green Injection

 

 

06.04.03 Oxymetholone  ®

unlicensed unlicensed

Tablets

05.01.03 Oxytetracycline 

Tablets

07.01.01 Oxytocin Syntocinon®

injection

08.01.05 Paclitaxel 

Injection

08.01.05 Paclitaxel - Albumin Bound Formulation Abraxane®

Intravenous Infusion

04.02.02 Paliperidone 

Depot Injection

05.03.05 Palivizumab Synagis®

Injection

01.09.04 Pancreatin Creon® Micro

Initiated by Paediatric consultant

01.09.04 Pancreatin Pancrex® V

Tablets
Tablets forte
Capsule

 

01.09.04 Pancreatin Creon®

Capsules

08.01.05 Panitumumab Vectibix®
08.01.05 Panobinostat Farydak®

tablet

01.03.05 Pantoprazole 

Injection

04.07.01 Paracetamol 

Tablets

Soluble tablets

Suppositories

 

04.07.01 Paracetamol 

Intravenous Infusion

 

Cautionary note: to ensure one checks timing of the previous paracetamol dose before administering the next dose.

 

Weight considerations ( e.g. >50kg)For patients weighing less than 50kg (use 15mg/kg qds)

04.07.01 Paracetamol Paediatric Solution

Paracetamol Paediatric Suspension

04.07.01 Paracetamol and codeine Co-codamol® 8/500

Tablets,

Capsule

 

Not to be prescribed by Secondary Care

04.07.01 Paracetamol and codeine Co-codamol ®15/500

Tablets

Capsules

Not to be prescribed in Secondary Care

04.07.01 Paracetamol and codeine Co-codamol® 30/500

Tablets

Capsules

 

Not to be prescribed as co-codamol in secondary care

04.07.01 Paracetamol and dihydrocodeine Co-dydramol®

Not for secondary care prescribing

04.08.02 Paraldehyde 

Injection, Enema. Hospital Only

04.03.03 Paroxetine 

tablets

08.01.05 Pazopanib Votrient®

Tablet

08.01 Pegaspargase Oncaspar®

Tablet

08.02.04 Peginterferon Alfa Pegasys®
08.02.04 Peginterferon Alfa ViraferonPeg®
08.02.04 Peginterferon Beta-1a Plegridy®

Injection

08.01.05 Pembrolizumab Keytruda®

infusion

08.01.03 Pemetrexed Alimta®

Injection

08.02.04 Pemrolizumab Keytruda®

Infusion

10.01.03 Penicillamine 
05.04.08 Pentamidine Isetionate Pantacarinat®

Injection

08.01.05 Pentostatin Nipent®

Injection

02.06.04 Pentoxifylline Trental®

Initiated by consultant immunologist for Behcets

01.02 Peppermint Oil 

Capsule

01.01.02 Peptac ® 

Compound sodium alginate liquid, to be prescribed generically

04.08.01 Perampanel Fycompa®
02.05.05.01 Perindopril erbumine or tert-butylamine 

tablets

08.01.05 Pertuzumab Perjeta®

Infusion

04.07.02 Pethidine 

Tablets, Injection

04.03.02 Phenelzine Nardil®

tablets

02.08.02 Phenindione 
04.08.01 Phenobarbital 

AmberTablets

 

Red Injection

01.07.03 Phenol, Oily 

injection

02.05.04 Phenoxybenzamine Hydrochloride 

Capsules

Injection

05.01.01.01 Phenoxymethylpenicillin 

Tablets

Syrup

02.05.04 Phentolamine Rogitine®, Regitin®

injection

02.07.02 Phenylephrine  
11.05 Phenylephrine  

Minims 2.5%

Minims 10%

04.08.01 Phenytoin Epanutin®

Injection

Solution for injection

04.08.01 Phenytoin 

Capsule

Oral solution

Tablets

03.09.01 Pholcodine Linctus 
01.06.04 Phosphates (Rectal) 

Enema

01.06.05 Picolax ® 

Oral Sachets

11.06 Pilocarpine 

Eye Drops 1%, 2%, 4%

Red Traffic Light  Minims 1%, 2%, 4% (Hospital Initiated)

Red Traffic Light  Ophthalmic Gel 4% (Hospital Initiated)

13.05.03 Pimecrolimus 1% Elidel®
06.01.02.03 Pioglitazone Actos®

Tablet

05.01.01.04 Piperacillin and Tazobactam 

Injection

 

Restricted Item restricted by indication as per the antibiotic guideline

04.09.03 Piracetam Nootropil®

Tablets

Oral Solution

03.11 pirfenidone Esbriet®
10.01.01 Piroxicam Feldene®

piroxicam gel

10.03.02 Piroxicam Feldene®

piroxicam gel

05.01.01.05 Pivmecillinam ® selexid

Tablets

Restricted Item Group 2 Restricted

For resistant urinary tract infection where no alternative oral agent is suitable. Shown by microbiogical culture and sensitivities

08.01.02 Pixantrone 
04.07.04.02 Pizotifen 

Tablets

04.07.04.02 Pizotifen 

elixir. Peadiatric consultant initiated only

01.06.05 Plenvu  plenvu®

oral powder sachets

 

Plenvu will be offered as an option when patients are unable to tolerate Moviprep or Picolax, or require restricted fluid intake

11.03.01 Polyhexamethylene biguanide 

unlicensedunlicensed

Eye Drops 0.02%

11.99.99.99 Polymyxin B/bacitracin Zinc Polyfax

Ointment

13.09 Polytar ® 
11.08.01 Polyvinyl Alchohol SnoTears®

Eye Drops 1.4%

08.02.04 Pomalidomide Imnovid®
08.01.05 Ponatinib Iclusig®
03.05.02 Poractant Alfa Curosurf®
07.04.03 Potassium Citrate 

 Potassium Citrate Mixture BP  

04.09.01 Pramipexole 
02.09 Prasugrel Efient®
02.12 Pravastatin  

tablets

05.05.05 PRAZIQUANTEL  

unlicensed unlicensed

 

Tablet

Unlicensed medicine - named patient use only

02.05.04 Prazosin 

Tablets

01.05.02 Prednisolone 

Rectal Foam Enemas

01.05.02 Prednisolone 

1mg, 2.5mg and 5mg Tablets soluble tablets

enteric coated tablets are for restricted use only .

06.03.02 Prednisolone 

Tablet, soluble tablet, oral solution 5mg/5mL

11.04.01 Prednisolone eye drops 

unlicensedunlicensed

0.05% Eye Drops

0.1% Eye Drops

11.04.01 Prednisolone eye drops 

Eye Drops 0.5%

Eye Drops 1%

Minims 0.5%

11.04.01 Prednisolone with Neomycin 

Eye Drops

04.08.01 Pregabalin 

capsules

From April 2019 pregabalin will be reclassified as class C controlled substance. Prescriptions will need to be physically signed by doctors; electronic copies will not be accepted by pharmacists - the total quantity will need to be written on the prescription in both words and figures and pharmacists will need to dispense the drugs within 28 days of the prescription being written

04.08.01 Primidone 

Tablets

10.01.04 Probenecid 

tablets

02.03.02 Procainamide 

Injection

05.01.01.01 Procaine Benzylpenicillin 
08.01.05 Procarbazine 

capsule 

04.06 Prochlorperazine 

Tablets, Buccal Tablet, Liquid (Prochlorperazine Maleate)

 

RedInjection (Prochlorperazine mesilate)

01.07.02 Proctosedyl ® 

ointment
suppositories

04.09.02 Procyclidine 

Tablets

Red Procyclidine Injection

06.04.01.02 Progesterone 

Injection

06.04.01.02 Progesterone pessaries  Cyclogest®

Pessaries

Hospital only Obs and Gynae consultant

08.02.02 Prograf ® 

Red NHSE funded indication are usually Hospital Only

05.04.01 Proguanil Hydrochloride Paludrine®

Tablet
For the treatment of malaria
Should not be prescribed for malaria prophylaxis on the NHS. Patients should obtain a supply on private prescription or purchase a supply "over the counter" as appropriate  

03.04.01 Promethazine 

Green Tablets, liquid

Red Injection

02.03.02 Propafenone 

Restricted Item Tablets

11.03.01 Propamidine  

Eye Drops 0.1%

01.02 Propantheline 

Tablet
For the treatment of hyperhidrosis
Also indicated for the treatment of adult enuresis

07.04.02 Propiverine Detrunorm®

Capsule m/r

02.04 Propranolol  

Tablet

Restricted Item Capsule MR & Liquid

Red Traffic Light Injection

06.02.02 Propylthiouracil 

Tablets

13.02.02 Proshield® 

For use in line with the Barrier Products Pathway

02.08.03 Protamine Sulphate 

Injection

06.05.01 Protirelin TRH

Injection 100 micrograms/ml, 2ml

11.07 Proxymetacaine 

0.5% Minims

11.07 Proxymetacaine with Fluorescein Sodium  

Minims

01.06.07 Prucalopride Resolor®

To be used in accordance with NICE TA

05.01.09 Pyrazinamide 

tablet

unlicensed unlicenced - Pyrazinamide Liquid. Consultant Paediatrician Only

10.02.01 Pyridostigmine Bromide Mestinon®

tablets

05.04.01 Pyrimethamine with Sulfadoxine Fansidar®

Tablets

04.02.01 Quetiapine 

Tablet,
MR tablet - restricted use only, (for patients whome are unable to comply with dosage regimen for standard release formulation)

06.07.01 Quinagolide Norprolac®

Tablets

05.04.01 Quinine dihydrochloride  

Injection

05.04.01 Quinine Sulfate  

Tablets

10.02.02 Quinine sulphate 

tablets

13.02.01 QV ® Cream  

Only for prescribing when 1st-line emollients have not been effective

01.03.05 Rabeprazole 

Tablets

08.03.04.02 Radium-223 dichloride 
06.04.01.01 Raloxifene Hydrochloride Evista®

Tablet

05.03.01 Raltegravir Isentress ®

Tablet
Note: Doses differ according to formulation used and thus tablets and chewable tablets are not equivalent. When prescribing, the formulation must be specified

08.01.03 Raltitrexed Tomudex®

Infusion

02.05.05.01 Ramipril 

capsule and tablets

11.08.02 Ranibizumab Lucentis®

Intravitreal Injection

01.03.01 Ranitidine 

Green Tablets and soluble tablets

Amber Oral solution (Paediatric use)

Red Injection

 

02.06.03 Ranolazine Ranexa®

Modified Release Tablets

 

04.09.01 Rasagiline 
10.01.04 Rasburicase Fastertec

injection

06.03.02 Regional emergency box for treatment of inborn errors of metabolism 

Regional emergency box for treatment of inborn errors of metabolism

08.01.05 Regorafenib Stivarga®

Injection

06.01.02.03 Repaglinide Prandin®

Tablet

03.04.02 Reslizumab Cinquil®

Injection

04.08.01 Retigabine 
11.08.01 Retinol Palimate, WSP, Light LP, LP & Wool Fat 

Eye Ointment

05.03.05 Ribavirin 

Tablet

Capsule

08.01.05 Ribociclib 

Approved for use in line with NICE TA

05.01.09 Rifampicin 

Capsules, Syrup, Injection

05.01.09 Rifampicin and Isoniazid Rifinah® 300 Rifinah® 150

tablet

05.01.09 Rifampicin and Isoniazid Rimactazid® 300

tablet

05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®

tablet

05.01.09 Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv®

tablet

05.01.07 Rifaximin 

550mg  tablets

Indicated for the prophylaxis of encephalopathy to be used in accordance with NICE TA337

05.03.01 Rilpivirine hydrochloride Edurant®

Tablet

04.09.03 Riluzole Rilutek®

Only Consultant can formerly diagnose and initate the treatment with Riluzole for motor neurone disease

11.04.01 Rimexolone Vexol®

Eye Drops 1%

06.06.02 Risedronate 

Tablets 35mg

06.06.02 Risedronate  

5mg Tablets

04.02.01 Risperidone 

Tablet

Liquid

04.02.02 Risperidone Risperdal Consta®

Depot Injection
Store in a refrigerator

05.03.01 Ritonavir Norvir®

Tablet
Note: Doses differ according to formulation used and thus tablets and chewable tablets are not equivalent. When prescribing, the formulation must be specified

08.02.03 Rituximab MabThera®Truxima ®

Injection

10.01.03 Rituximab (rheumatology) MabThera®

infusion

02.08.02 Rivaroxaban Xarelto®

Tablets

04.11 Rivastigmine 

Capsules

04.07.04.01 Rizatriptan Maxalt®

Tablets

03.03.03 Roflumilast Daxas®

Tablets

For treating Chronic Obstrustive Pulmonary Disease

04.09.01 Ropinirole 
02.12 Rosuvastatin 

Restricted ItemTablets

04.09.01 Rotigotine 
08.01.05 Rucaparib 

Approved in line with NICE TA611

08.01.05 Ruxolitinib Jakavi®

Tablet

02.15 Sacubitril valsartan Entresto®

Tablets

Neprilysin Inhibitors with Angiotensin-II Receptor Antagonists

 

03.01.01.01 Salbutamol 

CFC Free MDI, Easi-Breathe, DPI, Syrup, Injection, Nebules

 

 

 

Short acting beta agonist
  • 1st line = MDI + spacer
  • 2nd line = CFC free breath actuated (Salamol Easi-Breathe® - prescribe by brand)
  • 3rd line = DPI (Easyhaler® Salbutamol)NB Device expires 6 months after the foil pouch is opened
  • Nebules also available. Nebs may be diluted with 0.9% sodium chloride if needed

Restricted Item Red Salbutamol Tablets are Hopital only

GreySalbutamol 200mcg DPI is non formulary

07.01.03 Salbutamol 

Injection

 

Please refere chapter 3, section 3.1.1.1 for respiratory use

05.03.01 Saquinavir Invirase®

Tablet

10.01.03 Sarilumab   (Kevzara®)

Injection - prefilled syringe of pen

06.01.02.03 Saxagliptin Onglyza®

Tablet

01.07.02 Scheriproct ® ointment 

Ointment
Supositories

13.05.02 Sebco ® scalp ointment  
10.01.03 Secukinumab 

Injection - syringe or pre-filled pen.

13.05.03 Secukinumab 
04.09.01 Selegiline Hydrochloride 
06.01.02.03 Semaglutide Ozempic®

Injection

To be used as combination therapy

01.06.02 Senna 

Tablets, Syrup

 

04.03.03 Sertraline 

Tablet

07.04.05 Sildenafil 

Tablet
Prescribers should ensure that generic sildenafil tablets are used as the first
line PDE5 inhibitor of choice

11.08.01 Simple Eye Ointment 
03.09.02 Simple Linctus 
03.09.02 Simple Linctus, Paediatric BP 
02.12 Simvastatin 

Tablets

08.02.02 Sirolimus Rapamune®
06.01.02.03 Sitagliptin Januvia®

Tablet

07.04.03 Sodium Bicarbonate 
11.08.01 Sodium Chloride 

Eyes Drops 0.9%

Minims 0.9%

Red Traffic Light  Eye Drops 5% (Hospital initiated for at least 1st 3 months)

03.07 Sodium chloride 3%, 6% (Hypertonic) MucoClear®

Nebules

01.01.02 Sodium citrate 0.3M 
06.06.02 Sodium Clodronate 

400mg capsules

01.05.04 Sodium cromoglicate Nalcrom®

100mg capsules

03.03.01 Sodium Cromoglicate 

MDI

11.04.02 Sodium Cromoglicate 

Eye Drops 2%

05.01.07 Sodium fusidate 

Tablet, Suspension, Infusion
Microbiologist approval required in all cases

11.08.01 Sodium Hyaluronate 

Syringe

0.4% Preservative Free Eye Drops Unit Dose

02.05.01 Sodium nitroprusside 

Injection

01.06.02 Sodium Picosulfate 

Liquid
Sachets

04.02.03 Sodium valproate 

tablets

04.08.01 Sodium Valproate Epilim®

Standard-release and modified-release oral dosage forms

04.08.01 Sodium Valproate Epilim® Intravenous

intravenous injection

05.03.03.02 Sofosbuvir Sovaldi®

Tablet

05.03.03.02 Sofosbuvir, Velpatasvir and Voxilaprevir Vosevi®

Tablet

07.04.02 Solifenacin Vesicare®

Tablet

06.05.01 Somatropin Omnitrope® Humatrope® genotropin® and Zomacton®

The seven manufacturers have UK marketing authorisations for somatropin for the following indications:

Lilly (Humatrope): Growth hormone deficiency; Turner syndrome; CRI, short children born small for gestational age and SHOX deficiency

Ferring ( Zomacton): Growth Hormone deficiency and turner syndrome

Ipsen (NutropinAq): Growth hormone deficiency; Turner syndrome and CRI

Novo Nordisk (Norditropin SimpleXx): Growth Hormone deficiency; Turner syndrome; CRI and short children born small for gestation age

Pfizer (Genotropin): Growth hormone deficiency; Turner syndrome; CRI;Prader-Willi syndrome and short children born small for gestational age

Sandoz (Omnitrope): Growth Hormone deficiency; Turner syndrome;CRI; Prader-Willi syndrome and short children born small for gestational age

Merck Serono (Saizen): Growth Hormone deficiency; Turner syndrome; CRI and short children born small for gestational age

08.01.05 Sorafenib Nexavar®

Tablet

02.04 Sotalol 

Tablet

05.01.07 Spectinomycin 

Centre for Sexual Health Only

02.02.03 Spironolactone 

FIRST CHOICE

05.03.01 Stavudine Zerit®

Capsule, Oral Solution 

02.10.02 Streptokinase 

injection

05.01.09 Streptomycin Sulphate 

Injection

01.03.03 Sucralfate 

Tablets and Suspension

01.03.03 Sucralfate 

Enema

 

Unlicenced formulation

05.01.08 Sulfadiazine 

Tablets

01.05.01 Sulfasalazine salazopyrin

Tablets, Suspension

10.01.03 Sulfasalazine EC Salazopyrin EN-Tabs®

tablet

04.07.04.01 Sumatriptan 

Tablets

 

AmberSumatriptan Nasal Spray. Paediatric Consultant Initiated
AmberSumatriptan Injection. *for migraine and cluster headaches*

08.01.05 Sunitinib Sutent®

Capsule

13.05.02 Tacalcitol  
13.05.03 Tacrolimus Protopic®
07.04.05 Tadalafil Cialis®

Tablets 10mg, 20mg

08.02.04 Talimogene laherparepvac Imlygic®

injection

08.01.05 Talimogene laherparepvec Imlygic®
08.03.04.01 Tamoxifen 

Tablets 10mg, 20mg.

07.04.01 Tamsulosin 

Modified Release tablets

Modified Release Capsules

04.07.02 Tapentadol Palexia®

Modified release tablets

05.01.07 Tedizolid Sivextro®

200mg Tablets, Infusion

 

Microbiology Approval is requires in all cases

08.01.03 Tegafur with Uracil Uftoral®

Capsule

05.01.07 Teicoplanin 

Injection

05.03.03.02 Telaprevir Incivo®

Tablet

04.01.01 Temazepam 

Tablets, oral solution

05.01.01.02 Temocillin 

Injection

Restricted use only requiring microbiologist approval in all cases

08.01.05 Temozolomide Temodal®

capsule

08.01.05 Temsirolimus Torisel®

infusion

02.10.02 Tenecteplase Metalyse®
05.03.01 Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla®

Tablet

05.03.01 Tenofovir alafenamide, elvitegravir, cobicistat & emtricitabine Genvoya®

Tablet
Restricted to use in accordance with the NHS England commissioning guidance 

05.03.01 Tenofovir and Emtricitabine Truvada®

Tablet

05.03.01 Tenofovir Disproxil Viread®

Tablet

05.03.01 Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild®

Tablet
Restricted to use in accordance with the NHS England commissioning guidance.

05.02 Terbinafine 

Tablet

05.02 Terbinafine Lamisil®

Terbinafine hydrochloride 1%

Topical preparation, please consult chapter 13 for further information

03.01.01.01 Terbutaline 

 DPI, Respirator Solution, Respules (2ml)

 

 
  • Short-acting beta-agonist
  • Turbohaler and Respules available
  • Limited use where patient intolerant of salbutamol and in those patients whose condition is exacerbated by an aerosol

 

08.02.04 Teriflunomide Aubagio®
06.06.01 Teriparatide  Forsteo ®

Injection

06.05.02 Terlipressin Glypressin®

Injection 1mg Vial

06.04.02 Testosterone  

unlicensed

300micrograms/24hour patch

06.04.02 Testosterone gel  Tostran®

Gel 2%

06.04.02 Testosterone implant 

Implant

06.04.02 Testosterone undecanoate Nebido®

Intramuscular Injection

04.09.03 Tetrabenazine Xenazine® 25

Tablets

11.07 Tetracaine 

Eye Drops 1%

06.05.01 Tetracosactide Synacthen®

Injection


Available as:

Short Synacthen test 250mcg (IM/IV)

Depot for prolonged synacthen 1mg IM

08.02.04 Thalidomide Celgene®
03.01.03 Theophylline 

Modified Release Tablet

Theophylline has a narrow therapeutic index and troublesome interactions (especially with macrolides & nicotine).
N.B. PRESCRIBE BY BRAND - Be aware that oral modified release brands of theophylline and aminophylline are NOT interchangeable. All patients need to be maintained on the same brand as initally prescribed for them.

Red Liquid ( Unlicensed, specials )

08.01.01 Thiotepa 

Injection

11.08.02 Thymoxamine Moxisylyte ®

Eye Drops

05.05.07 TIABENDAZOLE  

Tablets

06.04.01.01 Tibolone Livial®

2.5mg tablets

02.09 Ticagrelor Brilique®
05.01.01.04 Ticarcillin  

Injection

 

Restricted Item Group 3 restricted

05.01.07 Tigecycline 

Injection
Microbiologist approval required in all cases

11.06 Timolol 

Eye Drops 0.25%

Eye Drops 0.5%

LA Eye Drops 0.25%

LA Eye Drops 0.5%

Single Dose Eye Drops 0.25%

Single Dose Eye Drops 0.5%

02.08.01 Tinzaparin 
08.01.03 Tioguanine Lanvis®

Tablet

03.01.02 Tiotropium 

For COPD

  • Prescribe by brand.
  • Despite being different doses; Braltus® and Spiriva® Handihaler and Respimat are clinically equivalent and produce the same amount of active ingredient in the body. 10 micrograms of Braltus® is equivalent to 18 micrograms of Spiriva® Handihaler and 5 micrograms of Respimat.
  • Capsules for Spiriva® Handihaler and Braltus® should be used for their intended device only.
  • Spiriva® should be prescribed/endorsed with the type of device intended on the prescription (either HandiHaler or Respimat).
  • The Braltus Zonda is significantly cheaper than Spiriva HandiHaler and product switching from the Spiriva product to Braltus Zonda is encouraged.

For Asthma

  • Only the Respimat® device is licensed for asthma
03.01.04 Tiotropium & olodaterol ® Spiolto Respimat
02.09 Tirofiban Aggrastat®

INJECTION

08.01.05 Tivozanib (Fotivda®)

Capsule 

10.02.02 Tizanidine Zanaflex®
05.01.04 Tobramycin 

 

Injection

 

 

05.01.04 Tobramycin 

nebuliser solution

05.01.04 Tobramycin inhaler TOBI Podhaler®

Inhaler

10.01.03 Tocilizumab RoActemra®

infusion

10.01.03 Tofacitinib (Xeljanz®)

Tablet

02.05.01 Tolazoline 

Injection.

Restricted Item Hospital, Paediatrics Only

07.04.02 Tolterodine 

Tablet

 

Restricted Item Information on restriction

   Capsule M/R   Modified Release Capsule are restricted

06.05.02 Tolvaptan Jinarc®

Tablets

04.08.01 Topiramate 

Tablets

Hard capsules

08.01.05 Topotecan Hycamtin®

Capsule and Injection

08.03.04.01 Toremifene Fareston®

Tablets 60mg

08.01.05 Trabectedin Yondelis®

Injection

04.07.02 Tramadol 

Capsules

Tablets

 

Red Injection

08.01.05 Trametinib Mekinist®

Tablet

02.11 Tranexamic Acid 

Tablets

 Red Traffic Light injection

08.01.05 Trastuzumab Herceptin®

Injection

08.01.05 Trastuzumab emtansine Kadcyla®

Infusion

11.06 Travoprost 

Eye Drops 40mcg/ml

11.06 Travoprost with Timolol 

Eye Drops Travoprost 40mcg/ml with Timolol 5mg/ml

04.03.01 Trazodone 

Capsule,

Tablet

Liquid

08.01.01 Treosulfan 
08.01.05 Tretinoin Vesanoid®

Capsule 

10.01.02.02 Triamcinolone Acetonide Kenalog®
10.01.02.02 Triamcinolone Acetonide Adcortyl®
04.02.01 Trifluoperazine 

Tablet

Oral solution

08.01.05 Trifluridine and Tipiracil  Lonsurf ®

Tablet

04.09.02 Trihexyphenidyl (Benzhexol)

Tablets

05.01.08 Trimethoprim 

Green Tablets, Suspension

 

Red Injection

05.01.13 Trimethoprim 
06.07.02 Triptorelin Gonapeptyl Depot®

Injection

08.03.04.02 Triptorelin Decapeptyl®

Injection

11.05 Tropicamide  

Eye Drops 0.5%

Eye Drop 1%

 

11.05 Tropicamide 0.28 mg and Phenylephrine hydrochloride 5.4 mg Mydriasert®
11.05 Tropicamide Minims 

Minims 0.5%

Minims 1%

07.04.02 Trospium 

Tablets 20mg, 60mg MR Capsules. As Per APC OAB Pathway

06.07.02 Ulipristal Esmya®

License suspended March 2020: MHRA update

As per MHRA Alert  Do not initiate or re-start treatment; monitor liver function in current and recent users **

 

07.03.05 Ulipristal EllaOne®

Tablet

13.02.01 Ultrabase® Ointment 
03.01.02 Umeclidinium Incruse Ellipta®
03.01.04 Umeclidinium & vilanterol Anoro Ellipta®
02.10.02 Urokinase 
 

Restricted Drug injection

01.09.01 Ursodeoxycholic acid 

capsules
suspension

01.05.03 Ustekinumab  Stelera ®
10.01.03 Ustekinumab (Stelara)

Injection

13.05.03 Ustekinumab 
05.03.02.01 Valaciclovir Valtrex®

Tablets

*Only to be prescribed on advice of microbiologist. Indication for treatment of HSV PCR Positive viral meningitis ( not for encephalitis for which iv aciclovir must be used)*

05.03.02.02 Valganciclovir Valcyte®

Tablet, Oral solution

Prevention of cytomegalovirus disease following solid organ transplantion.
Complete course should be provided from transplant centre - not funded for prescribing in primary care 

04.02.03 Valproic Acid Depakote®

Tablet

02.05.05.02 Valsartan 

Capsules, Tablets

05.01.07 Vancomycin 

Green Capsules

 

 

05.01.07 Vancomycin 

Injection

07.04.05 Vardenafil Levitra®

Tablets

04.10.02 Varenicline Champix®

tablets

 

To be prescribed and initiated by specialised service

06.05.02 Vasopressin Pitressin®

A Argipressin

Injection

01.05.03 Vedolizumab 

to be used in accordance with NICE TA352 and NICE TA342

13.08.02 Veil ® 

ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo)  

08.01.05 Vemurafenib Zelboraf®

Tablets

08.01.05 Vemurafenib  (Zelboraf® )

tablet

08.01.05 Venetoclax Venclyxto ®

Tablet

04.03.04 Venlafaxine 

Tablet, Capsule MR, Tablet MR

Note :

There has been a price change in the XL formulation and the 225mg strength is relatively costly. Hence the recommendation is not to prescribe 225mg tablets, but to prescribe the others strengths in order to achieve the dose required

02.06.02 Verapamil 

Tablets and Modified Release Tablets

Red Traffic Lightverapamil Injection

11.08.02 Verteporfin Visudyne®

Injection

08.01.04 Vinblastine Sulphate 

Injection

08.01.04 Vincristine Sulphate 

injection

08.01.04 Vindesine Sulphate Eldisine®

injection

08.01.04 Vinorelbine 

Injection, capsule

05.02 Voriconazole Vfend®

Tablets, Injection

11.03.02 Voriconazole 

unlicensedunlicensed

1% Eye Drops

04.03.03 Vortioxetine 

Tablets

08.01.05 Vosaroxin Qinprezo

Injection

02.08.02 Warfarin 

Tablets

11.08.01 White Soft Paraffin 57.3%, Liquid Paraffin 42.5% 

Eye Ointment

13.02.01 White Soft Paraffin BP 
01.07.02 Xyloproct ® 

ointment

03.03.02 Zafirlukast 
05.03.04 Zanamivir  Dectova®

Consultant microbiologist authorisation only

05.03.04 Zanamivir inhalation Relenza®
13.02.01 Zerobase ® gel  
13.02.01 Zerocream ® 
13.02.01 Zeroderm ® Ointment  
13.02.01 Zerodouble ® Gel  
05.03.01 Zidovudine Retrovir®

Capsule

05.03.01 Zidovudine and Lamivudine Combivir®

Tablet

13.02.02 Zinc and Castor Oil Cream 15% 
06.06.02 Zoledronic Acid Aclasta®

5mg Intravenous Infusion

06.06.02 Zoledronic Acid Zometa®

4mg Intravenous Infusion

04.01.01 Zolpidem 

Tablets

04.08.01 Zonisamide Zonegran®

Capsules

04.01.01 Zopiclone 
04.02.01 Zuclopenthixol Clopixol®

Tablet

04.02.01 Zuclopenthixol Acetate Clopixol Acuphase®

Zuclopenthixol Acetate (acuphase)

04.02.02 Zuclopenthixol Decanoate Clopixol®

Depot Injection

Northern Lincolnshire